Related references
Note: Only part of the references are listed.Membrane skeleton modulates erythroid proteome remodeling and organelle clearance
Yijie Liu et al.
BLOOD (2021)
PLEK2 promotes osteosarcoma tumorigenesis and metastasis by activating the PI3K/AKT signaling pathway
Yang Liu et al.
ONCOLOGY LETTERS (2021)
microRNA-873 inhibits self-renewal and proliferation of pancreatic cancer stem cells through pleckstrin-2-dependent PI3K/AKT pathway
Xiao-Li Yang et al.
CELLULAR SIGNALLING (2021)
Pleckstrin-2 as a Prognostic Factor and Mediator of Gastric Cancer Progression
Jun Wang et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2021)
PLEK2 mediates metastasis and vascular invasion via the ubiquitin-dependent degradation of SHIP2 in non-small cell lung cancer
Dong-Ming Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Diaphanous-related formin mDia2 regulates beta2 integrins to control hematopoietic stem and progenitor cell engraftment
Yang Mei et al.
NATURE COMMUNICATIONS (2020)
PLEK2 Gene Upregulation Might Independently Predict Shorter Progression-Free Survival in Lung Adenocarcinoma
Wenqian Zhang et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2020)
PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway
Hui Shen et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms
Baobing Zhao et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Targeting the PI3K pathway in cancer: are we making headway?
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Yu-Ru Lee et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Emerging treatments for classical myeloproliferative neoplasms
Alessandro M. Vannucchi et al.
BLOOD (2017)
PTEN Regulates PI(3,4)P2 Signaling Downstream of Class I PI3K
Mouhannad Malek et al.
MOLECULAR CELL (2017)
Nuclear Condensation during Mouse Erythropoiesis Requires Caspase-3-Mediated Nuclear Opening
Baobing Zhao et al.
DEVELOPMENTAL CELL (2016)
JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
Maria Kleppe et al.
CANCER DISCOVERY (2015)
Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer
Sun-Yong Kim et al.
ONCOTARGET (2015)
The anti-factor Xa range for low molecular weight heparin thromboprophylaxis
Matthew Y. Wei et al.
HEMATOLOGY REPORTS (2015)
Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis
Baobing Zhao et al.
HAEMATOLOGICA (2014)
The cellular thermal shift assay for evaluating drug target interactions in cells
Rozbeh Jafari et al.
NATURE PROTOCOLS (2014)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Rationale for Targeting the PI3K/Akt/mTOR Pathway in Myeloproliferative Neoplasms
Niccolò Bartalucci et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma
Manik Chatterjee et al.
HAEMATOLOGICA (2013)
Ubiquitin-dependent Regulation of Phospho-AKT Dynamics by the Ubiquitin E3 Ligase, NEDD4-1, in the Insulin-like Growth Factor-1 Response
Chuan-Dong Fan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Broad Coverage of Commercially Available Lead-like Screening Space with Fewer than 350,000 Compounds
Jonathan B. Baell
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
JAK/STAT signaling in hematological malignancies
W. Vainchenker et al.
ONCOGENE (2013)
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms
Mohamad Bassam Sonbol et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis (vol 149, pg 1098, 2012)
Chia-Hsin Chan et al.
CELL (2012)
ZINC: A Free Tool to Discover Chemistry for Biology
John J. Irwin et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry
Jonathan Clark et al.
NATURE METHODS (2011)
MolProbity: all-atom structure validation for macromolecular crystallography
Vincent B. Chen et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
Juan Li et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
PH Domain-Only Protein PHLDA3 Is a p53-Regulated Repressor of Akt
Tatsuya Kawase et al.
CELL (2009)
The E3 Ligase TRAF6 Regulates Akt Ubiquitination and Activation
Wei-Lei Yang et al.
SCIENCE (2009)
Enucleation of cultured mouse fetal erythroblasts requires Rac GTPases and mDia2
Peng Ji et al.
NATURE CELL BIOLOGY (2008)
Pleckstrin-2 selectively interacts with phosphatidylinositol 3-kinase lipid products and regulates actin organization and cell spreading
Norihisa Hamaguchi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Microcalorimetry of biological macromolecules
Peter L. Privalov et al.
BIOPHYSICAL CHEMISTRY (2007)
PI3K regulates pleckstrin-2 in T-cell cytoskeletal reorganization
Tami L. Bach et al.
BLOOD (2007)
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
Omer H. Yilmaz et al.
NATURE (2006)
PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention
Jiwang Zhang et al.
NATURE (2006)
New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies
R Farid et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
Novel procedure for modeling ligand/receptor induced fit effects
W Sherman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
R Kralovics et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
PI3K induced actin filament remodeling through Akt and p70S6K1: implication of essential role in cell migration
Y Qian et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
Pursuing the leadlikeness concept in pharmaceutical research
MM Hann et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2004)
Share Paper
